Profile data is unavailable for this security.
About the company
Devyser Diagnostics AB is a Sweden-based company engaged in development, manufacture ad sale of kits for genetic testing in routing diagnostic to laboratories. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The company has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The Company provides its products in more than 45 countries.
- Revenue in SEK (TTM)196.00m
- Net income in SEK-54.20m
- Incorporated2004
- Employees127.00
- LocationDevyser Diagnostics ABInstrumentvagen 19HAGERSTEN 126 53SwedenSWE
- Phone+46 856215850
- Websitehttps://www.devyser.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alligator Bioscience AB | 45.71m | -234.30m | 1.10bn | 51.00 | -- | -- | -- | 24.15 | -0.362 | -0.362 | 0.0696 | -0.0125 | 0.2653 | -- | 9.47 | 788,034.50 | -136.02 | -73.26 | -367.94 | -91.33 | -- | -- | -512.61 | -811.68 | -- | -35.61 | 5.17 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Arcticzymes Technologies ASA | 115.86m | 17.27m | 1.24bn | 68.00 | 71.88 | 4.01 | 53.02 | 10.74 | 0.3443 | 0.3443 | 2.30 | 6.17 | 0.3562 | 0.4228 | 6.29 | 1,731,471.00 | 5.31 | 15.58 | 5.66 | 17.22 | 95.50 | 96.69 | 14.91 | 33.23 | 12.14 | -- | 0.0327 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
| XSpray Pharma AB (publ) | 0.00 | -212.58m | 1.59bn | 26.00 | -- | 2.90 | -- | -- | -7.66 | -7.66 | 0.00 | 20.00 | 0.00 | -- | -- | 0.00 | -33.92 | -18.38 | -36.11 | -19.26 | -- | -- | -- | -- | 2.24 | -- | 0.0536 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Diamyd Medical AB | 186.00k | -139.62m | 1.66bn | 25.00 | -- | 8.76 | -- | 8,933.09 | -1.55 | -1.55 | 0.0021 | 1.96 | 0.0009 | -- | 3.35 | 7,440.00 | -68.99 | -25.46 | -76.65 | -28.37 | -7,386.02 | -1,419.23 | -75,065.59 | -5,896.43 | -- | -90.74 | 0.1391 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
| Cereno Scientific AB | 0.00 | -59.13m | 1.69bn | 5.00 | -- | 7.00 | -- | -- | -0.281 | -0.281 | 0.00 | 0.8598 | 0.00 | -- | -- | 0.00 | -24.71 | -16.81 | -26.65 | -18.26 | -- | -- | -- | -- | -- | -10.70 | 0.1843 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| Nanoform Finland Oyj | 28.40m | -272.23m | 1.77bn | 166.00 | -- | 2.28 | -- | 62.26 | -0.2974 | -0.2974 | 0.031 | 0.774 | 0.0287 | 100.58 | 4.29 | 14,687.82 | -27.47 | -27.13 | -30.12 | -29.48 | -576.50 | -604.26 | -958.65 | -1,023.70 | 6.60 | -- | 0.091 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Egetis Therapeutics AB (publ) | 62.80m | -326.90m | 1.79bn | 30.00 | -- | 3.79 | -- | 28.51 | -1.22 | -1.22 | 0.2326 | 1.62 | 0.0913 | 28.00 | 4.33 | 2,325,926.00 | -47.48 | -33.02 | -53.33 | -36.46 | 82.17 | -- | -520.22 | -357.72 | 2.53 | -144.77 | 0.2014 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| Devyser Diagnostics AB | 196.00m | -54.20m | 1.81bn | 127.00 | -- | 4.92 | -- | 9.25 | -3.33 | -3.33 | 12.05 | 22.35 | 0.3855 | 1.61 | 5.42 | 1,661,017.00 | -10.68 | -8.97 | -12.15 | -10.15 | 83.11 | 80.14 | -27.70 | -23.91 | 4.01 | -- | 0.1498 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
| Vicore Pharma Holding AB | 104.24m | -212.94m | 2.07bn | 26.00 | -- | 4.23 | -- | 19.85 | -2.15 | -2.15 | 1.01 | 4.38 | 0.2589 | -- | 14.41 | 4,343,459.00 | -52.89 | -58.65 | -59.34 | -65.58 | -- | -- | -204.27 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| BioInvent International AB | 61.15m | -334.52m | 2.67bn | 109.00 | -- | 2.17 | -- | 43.69 | -5.08 | -5.08 | 0.929 | 18.73 | 0.041 | -- | 1.29 | 550,927.90 | -22.41 | -17.50 | -23.68 | -18.64 | -- | -- | -547.02 | -131.63 | 13.34 | -- | 0.0169 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
Data as of Jul 30 2024. Currency figures normalised to Devyser Diagnostics AB's reporting currency: Swedish Krona SEK
26.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Swedbank Robur Fonder ABas of 28 Jun 2024 | 1.30m | 8.08% |
| Fj�rde AP-fondenas of 30 Jun 2023 | 1.10m | 6.84% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 30 Jun 2023 | 987.75k | 6.12% |
| Deka Investment GmbHas of 31 Mar 2024 | 420.20k | 2.60% |
| Aktia Bank Plc (Investment Management)as of 28 Jun 2024 | 170.00k | 1.05% |
| E. �hman J :or Fonder ABas of 31 May 2024 | 138.55k | 0.86% |
| Barius Capital Management GmbHas of 31 Mar 2024 | 67.79k | 0.42% |
| Fidecum AGas of 28 Mar 2024 | 11.66k | 0.07% |
| GSAM + Spee Asset Management AGas of 31 Mar 2024 | 9.65k | 0.06% |
| Lupus alpha Asset Management AGas of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 28 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
